Scholarlink

Introduction <p>This study aimed to compare the real-world effectiveness of upadacitinib vs. other Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA).</p> Methods <p>Data were extracted from the Adelphi RA Disease Specific Programme™ (DSP), a cross-sectional survey administered to rheumatologists and their patients in the EU, UK, Japan, Canada, and the US from July 2021 to February 2022. Patients receiving upadacitinib 15&#xa0;mg or other JAKis, including tofacitinib, baricitinib, or peficitinib, for ≥ 6&#xa0;months were included in the study. Data captured at treatment initiation and follow-up (≥ 6&#xa0;months) included physician-evaluated pain rating and Disease Activity Score in 28 joints (DAS28). Fatigue and medication adherence were recorded at follow-up only. Inverse-probability-weighted regression adjustment was used to compare clinical outcomes at follow-up between patients treated with upadacitinib vs. other JAKis.</p> Results <p>Of 1440 total patients with RA, 1205 patients received upadacitinib and 235 received other JAKis. At study initiation, the majority of patients in both treatment groups had moderate/high disease activity (upadacitinib: 63.5%, other JAKis: 51.3%). At the most recent follow-up, after adjusting for differences in clinical characteristics between groups, patients treated with upadacitinib were significantly more likely to have attained physician-reported remission (54.3% vs. 44.1%, <i>P</i> = 0.030), have no pain (43.4% vs. 32.8%, <i>P</i> = 0.016), and have complete medication adherence (59.5% vs. 49.0%, <i>P</i> = 0.025) compared with patients treated with other JAKis. Of patients treated with upadacitinib, 42.5% were reported as having no fatigue compared with 36.1% of patients receiving other JAKis (<i>P</i> = 0.173).</p> Conclusions <p>This real-world study of patients with RA showed that greater proportions of patients who received upadacitinib attained physician-reported DAS28 remission, absence of pain, and complete adherence to medication compared with patients receiving other JAKis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月14日

查看全文
  • Peter C. Taylor,
  • Aditi Kadakia,
  • Jack Milligan,
  • Ana Romero,
  • Oliver Howell,
  • Pankaj A. Patel,
  • Sophie Barlow,
  • Roberto Caporali

摘要

Introduction

This study aimed to compare the real-world effectiveness of upadacitinib vs. other Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA).

Methods

Data were extracted from the Adelphi RA Disease Specific Programme™ (DSP), a cross-sectional survey administered to rheumatologists and their patients in the EU, UK, Japan, Canada, and the US from July 2021 to February 2022. Patients receiving upadacitinib 15 mg or other JAKis, including tofacitinib, baricitinib, or peficitinib, for ≥ 6 months were included in the study. Data captured at treatment initiation and follow-up (≥ 6 months) included physician-evaluated pain rating and Disease Activity Score in 28 joints (DAS28). Fatigue and medication adherence were recorded at follow-up only. Inverse-probability-weighted regression adjustment was used to compare clinical outcomes at follow-up between patients treated with upadacitinib vs. other JAKis.

Results

Of 1440 total patients with RA, 1205 patients received upadacitinib and 235 received other JAKis. At study initiation, the majority of patients in both treatment groups had moderate/high disease activity (upadacitinib: 63.5%, other JAKis: 51.3%). At the most recent follow-up, after adjusting for differences in clinical characteristics between groups, patients treated with upadacitinib were significantly more likely to have attained physician-reported remission (54.3% vs. 44.1%, P = 0.030), have no pain (43.4% vs. 32.8%, P = 0.016), and have complete medication adherence (59.5% vs. 49.0%, P = 0.025) compared with patients treated with other JAKis. Of patients treated with upadacitinib, 42.5% were reported as having no fatigue compared with 36.1% of patients receiving other JAKis (P = 0.173).

Conclusions

This real-world study of patients with RA showed that greater proportions of patients who received upadacitinib attained physician-reported DAS28 remission, absence of pain, and complete adherence to medication compared with patients receiving other JAKis.